© 2001 by European Society of Cardiology
Copyright © 2000, European Society of Cardiology
Antiarrhythmic drug carvedilol inhibits HERG potassium channels
a3rd Department of Internal Medicine (Cardiology), University of Heidelberg Medical School, Bergheimerstrasse 58, D-69115 Heidelberg, Germany
bDepartment of Physiology and Pathophysiology University of Heidelberg Medical School, Bergheimerstrasse 58, D-69115 Heidelberg, Germany
* Corresponding author. Tel.: +49-622-156-8682; fax: +49-622-156-5515 johann_kiehn{at}ukl.uni-heidelberg.de
Objective: The aryloxypropanolamine carvedilol is a multiple action cardiovascular drug with blocking effects on 
-receptors, β-receptors, Ca2+-channels, Na+-channels and various native cardiac K+ channels, thereby prolonging the cardiac action potential. In a number of clinical trials with patients suffering from congestive heart failure, carvedilol appeared to be superior to other β-blocking agents in reducing total mortality. Given the multiple pharmacological actions of carvedilol, this may be due to specific channel blockade rather than β-antagonistic activity. Since human ether-a-go-go related gene (HERG) K+channels play a critical role in the pathogenesis of cardiac arrhythmias and sudden cardiac death, the effects of carvedilol on HERG K+channels were investigated. Methods: Double-electrode voltage-clamp experiments were performed on HERG potassium channels which were expressed heterologously in Xenopus oocytes. Results: Carvedilol at a concentration of 10 µM blocked HERG potassium tail currents by 47%. The electrophysiological characteristics of HERG, i.e. activation, steady-state inactivation and recovery from inactivation were not affected by carvedilol. Inhibition of current gradually increased from 0% immediately after the test pulse to about 80% at 600 ms with subsequent marginal changes of current kinetics during the resting 29 s, indicating a very fast open channel block by carvedilol as the major blocking mechanism. Conclusion: This is the first study demonstrating that carvedilol blocks HERG potassium channels. The biophysical data presented in this study with a potentially antiarrhythmic effect may contribute to the positive outcome of clinical trials with carvedilol.
KEYWORDS Adrenergic (ant)agonists; Antiarrhythmic agents; K-channel; Single channel currents; Ion channels
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D.-Y. Zhan, S. Morimoto, C.-K. Du, Y.-Y. Wang, Q.-W. Lu, A. Tanaka, T. Ide, Y. Miwa, F. Takahashi-Yanaga, and T. Sasaguri Therapeutic effect of {beta}-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation Cardiovasc Res, October 1, 2009; 84(1): 64 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. V. Naccarelli Antiadrenergic Therapy in the Control of Atrial Fibrillation Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S33 - S43. [Abstract] [PDF]
|
|
|
|
|
|
P. R. Kowey A Review of Carvedilol Arrhythmia Data in Clinical Trials Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S59 - S68. [Abstract] [PDF]
|
|
|
|
 |
|
 J. McMurray, L. Kober, M. Robertson, H. Dargie, W. Colucci, J. Lopez-Sendon, W. Remme, D. N. Sharpe, and I. Ford Antiarrhythmic effect of carvedilol after acute myocardial infarction: Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial J. Am. Coll. Cardiol., February 15, 2005; 45(4): 525 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Pratt Three decades of clinical trials with beta-blockers: The contribution of the CAPRICORN trial and the effect of carvedilol on serious arrhythmias J. Am. Coll. Cardiol., February 15, 2005; 45(4): 531 - 532. [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Karle, E. Zitron, W. Zhang, G. Wendt-Nordahl, S. Kathofer, D. Thomas, B. Gut, E. Scholz, C.-F. Vahl, H. A. Katus, et al. Human Cardiac Inwardly-Rectifying K+ Channel Kir2.1b Is Inhibited by Direct Protein Kinase C-Dependent Regulation in Human Isolated Cardiomyocytes and in an Expression System Circulation, September 17, 2002; 106(12): 1493 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Thomas, B. Gut, G. Wendt-Nordahl, and J. Kiehn The Antidepressant Drug Fluoxetine Is an Inhibitor of Human Ether-A-Go-Go-Related Gene (HERG) Potassium Channels J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 543 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A Karle and J. Kiehn An ion channel 'addicted' to ether, alcohol and cocaine: the HERG potassium channel Cardiovasc Res, January 1, 2002; 53(1): 6 - 8. [Full Text] [PDF]
|
|